1. Home
  2. OMH vs MBIO Comparison

OMH vs MBIO Comparison

Compare OMH & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ohmyhome Limited

OMH

Ohmyhome Limited

N/A

Current Price

$1.20

Market Cap

32.1M

Sector

Finance

ML Signal

N/A

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.76

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OMH
MBIO
Founded
2015
2015
Country
Singapore
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.1M
5.8M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
OMH
MBIO
Price
$1.20
$0.76
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
21.2K
30.9K
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.40
N/A
Revenue Next Year
$23.07
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.59
$0.53
52 Week High
$4.33
$7.00

Technical Indicators

Market Signals
Indicator
OMH
MBIO
Relative Strength Index (RSI) 41.19 42.12
Support Level $1.15 $0.71
Resistance Level $1.38 $1.00
Average True Range (ATR) 0.07 0.05
MACD -0.01 0.00
Stochastic Oscillator 10.34 37.73

Price Performance

Historical Comparison
OMH
MBIO

About OMH Ohmyhome Limited

Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: